GNI Group (FRA:3G6) Valuation Rank


FRA:3G6 GNI Group Ltd FRA:3G6
86 GF Score
Price €13.70
GF Value €14.66
! 5 Warning Signs
View Full Analysis

What is GNI Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

GNI Group Valuation Rank Related Terms

FRA:3G6
86GF Score
GNI Group Ltd FRA:3G6
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GNI Group (FRA:3G6) Overvalued in 2026?

Based on GuruFocus' analysis, GNI Group stock appears to be undervalued. The current stock price of €13.70 is trading 6.5% below its estimated GF Value™ of €14.66.

Key valuation signals for FRA:3G6:

  • Valuation Rank:
  • GF Value™: €14.66 vs. price of €13.70 (6.5% below fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the FRA:3G6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GNI Group Business Description

Other Exchanges 2160:Japan
Address 2-2-2 Nihonbashi Honcho, 3rd Floor, Nihonbashi Honcho YS Building, Chuo-ku, Tokyo, JPN, 103-0023
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
86GF Score

Get the complete analysis for FRA:3G6

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.70
Price
€14.66
GF Value